Anti-inflammatory and immunomodulating properties of statins

An additional tool for the therapeutic approach of systemic autoimmune diseases?

Pier Luigi Meroni, Cristina Luzzana, Donatella Ventura

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Cardiovascular diseases secondary to accelerated atherosclerosis are now accepted as a cause of mortality and morbidity in patients suffering from systemic lupus erythematosus and rheumatoid arthritis. More recently, atherosclerosis is emerging as one of the most serious complications in the anti-phospholipid syndrome, although large epidemiological studies, such as those performed in lupus and rheumatoid arthritis patients, have not been performed up to now. Classical risk factors (dislipidemia, hypertension, diabetes, smoking, etc.) and steroid therapy cannot completely explain the high prevalence of cardiovascular complications in systemic autoimmune diseases. Since the modern view defines atherosclerosis as a chronic inflammatory disorder, it has been suggested that systemic inflammation and soluble immune mediators (circulating autoantibodies, immune-complexes, complement activation products) might play a role in accelerating vessel pathology. The main target appears to be the endothelium because of its ability to switch to a pro-adhesive, pro-inflammatory and pro-coagulant surface in response to these mediators. Recent advances in the knowledge of the pharmacology of statins have indicated that these drugs rather than to be simple cholesterol lowering molecules display a pleiotropic effects on several mechanisms involved in the atherosclerotic plaque formation. Their anti-inflammatory activity and particularly their ability to downregulate endothelial cell activation induced by different stimuli strongly suggest their possible use in conditions in which the systemic inflammation and the endothelial activation/damage are thought to represent key pathogenic mechanisms.

Original languageEnglish
Pages (from-to)263-277
Number of pages15
JournalClinical Reviews in Allergy and Immunology
Volume23
Issue number3
DOIs
Publication statusPublished - Dec 2002

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Autoimmune Diseases
Atherosclerosis
Aptitude
Anti-Inflammatory Agents
Rheumatoid Arthritis
Inflammation
Coagulants
Antiphospholipid Syndrome
Complement Activation
Atherosclerotic Plaques
Antigen-Antibody Complex
Systemic Lupus Erythematosus
Adhesives
Autoantibodies
Endothelium
Epidemiologic Studies
Cardiovascular Diseases
Therapeutics
Down-Regulation

Keywords

  • Atherosclerosis
  • Autoimmune diseases
  • Inflammation
  • Statins

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Anti-inflammatory and immunomodulating properties of statins : An additional tool for the therapeutic approach of systemic autoimmune diseases? / Meroni, Pier Luigi; Luzzana, Cristina; Ventura, Donatella.

In: Clinical Reviews in Allergy and Immunology, Vol. 23, No. 3, 12.2002, p. 263-277.

Research output: Contribution to journalArticle

@article{1636166d37cf42c19fa757a3b53837ac,
title = "Anti-inflammatory and immunomodulating properties of statins: An additional tool for the therapeutic approach of systemic autoimmune diseases?",
abstract = "Cardiovascular diseases secondary to accelerated atherosclerosis are now accepted as a cause of mortality and morbidity in patients suffering from systemic lupus erythematosus and rheumatoid arthritis. More recently, atherosclerosis is emerging as one of the most serious complications in the anti-phospholipid syndrome, although large epidemiological studies, such as those performed in lupus and rheumatoid arthritis patients, have not been performed up to now. Classical risk factors (dislipidemia, hypertension, diabetes, smoking, etc.) and steroid therapy cannot completely explain the high prevalence of cardiovascular complications in systemic autoimmune diseases. Since the modern view defines atherosclerosis as a chronic inflammatory disorder, it has been suggested that systemic inflammation and soluble immune mediators (circulating autoantibodies, immune-complexes, complement activation products) might play a role in accelerating vessel pathology. The main target appears to be the endothelium because of its ability to switch to a pro-adhesive, pro-inflammatory and pro-coagulant surface in response to these mediators. Recent advances in the knowledge of the pharmacology of statins have indicated that these drugs rather than to be simple cholesterol lowering molecules display a pleiotropic effects on several mechanisms involved in the atherosclerotic plaque formation. Their anti-inflammatory activity and particularly their ability to downregulate endothelial cell activation induced by different stimuli strongly suggest their possible use in conditions in which the systemic inflammation and the endothelial activation/damage are thought to represent key pathogenic mechanisms.",
keywords = "Atherosclerosis, Autoimmune diseases, Inflammation, Statins",
author = "Meroni, {Pier Luigi} and Cristina Luzzana and Donatella Ventura",
year = "2002",
month = "12",
doi = "10.1385/CRIAI:23:3:263",
language = "English",
volume = "23",
pages = "263--277",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Anti-inflammatory and immunomodulating properties of statins

T2 - An additional tool for the therapeutic approach of systemic autoimmune diseases?

AU - Meroni, Pier Luigi

AU - Luzzana, Cristina

AU - Ventura, Donatella

PY - 2002/12

Y1 - 2002/12

N2 - Cardiovascular diseases secondary to accelerated atherosclerosis are now accepted as a cause of mortality and morbidity in patients suffering from systemic lupus erythematosus and rheumatoid arthritis. More recently, atherosclerosis is emerging as one of the most serious complications in the anti-phospholipid syndrome, although large epidemiological studies, such as those performed in lupus and rheumatoid arthritis patients, have not been performed up to now. Classical risk factors (dislipidemia, hypertension, diabetes, smoking, etc.) and steroid therapy cannot completely explain the high prevalence of cardiovascular complications in systemic autoimmune diseases. Since the modern view defines atherosclerosis as a chronic inflammatory disorder, it has been suggested that systemic inflammation and soluble immune mediators (circulating autoantibodies, immune-complexes, complement activation products) might play a role in accelerating vessel pathology. The main target appears to be the endothelium because of its ability to switch to a pro-adhesive, pro-inflammatory and pro-coagulant surface in response to these mediators. Recent advances in the knowledge of the pharmacology of statins have indicated that these drugs rather than to be simple cholesterol lowering molecules display a pleiotropic effects on several mechanisms involved in the atherosclerotic plaque formation. Their anti-inflammatory activity and particularly their ability to downregulate endothelial cell activation induced by different stimuli strongly suggest their possible use in conditions in which the systemic inflammation and the endothelial activation/damage are thought to represent key pathogenic mechanisms.

AB - Cardiovascular diseases secondary to accelerated atherosclerosis are now accepted as a cause of mortality and morbidity in patients suffering from systemic lupus erythematosus and rheumatoid arthritis. More recently, atherosclerosis is emerging as one of the most serious complications in the anti-phospholipid syndrome, although large epidemiological studies, such as those performed in lupus and rheumatoid arthritis patients, have not been performed up to now. Classical risk factors (dislipidemia, hypertension, diabetes, smoking, etc.) and steroid therapy cannot completely explain the high prevalence of cardiovascular complications in systemic autoimmune diseases. Since the modern view defines atherosclerosis as a chronic inflammatory disorder, it has been suggested that systemic inflammation and soluble immune mediators (circulating autoantibodies, immune-complexes, complement activation products) might play a role in accelerating vessel pathology. The main target appears to be the endothelium because of its ability to switch to a pro-adhesive, pro-inflammatory and pro-coagulant surface in response to these mediators. Recent advances in the knowledge of the pharmacology of statins have indicated that these drugs rather than to be simple cholesterol lowering molecules display a pleiotropic effects on several mechanisms involved in the atherosclerotic plaque formation. Their anti-inflammatory activity and particularly their ability to downregulate endothelial cell activation induced by different stimuli strongly suggest their possible use in conditions in which the systemic inflammation and the endothelial activation/damage are thought to represent key pathogenic mechanisms.

KW - Atherosclerosis

KW - Autoimmune diseases

KW - Inflammation

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=0036887769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036887769&partnerID=8YFLogxK

U2 - 10.1385/CRIAI:23:3:263

DO - 10.1385/CRIAI:23:3:263

M3 - Article

VL - 23

SP - 263

EP - 277

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 3

ER -